It has been about a month since the last earnings report for Zoetis (ZTS). Shares have added about 1.7% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the ...

Shares of Zoetis ZTS have plunged 24.8% year to date, amid mounting safety concerns surrounding its monoclonal antibody osteoarthritis (OA)pain therapies — Librela for dogs and Solensia for cats. With ...

Zoetis Inc (NYSE:ZTS) shares plummeted 14.79% in pre-market trading on November 4, 2025, despite the animal health company reporting third-quarter earnings that beat analyst expectations. The ...

(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K. (b) Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign ...

Zoetis reported revenue of $2.4 billion for the third quarter, representing a 4% year-over-year increase on an organic operational basis. This growth was driven entirely by price increases (4%) with ...

Zoetis Inc. reported its third-quarter earnings for 2025, surpassing earnings per share (EPS) expectations with an actual EPS of $1.70 against a forecast of $1.62, marking a 4.94% surprise. However, ...

ZTS is fundamentally a companion animal company, with the segment driving 68% of 2024 revenue and projected to reach 71% by 2030, fueled by aging pet demographics in the US. OA pain franchise, Librela ...

Zoetis remains the global leader in animal health, with 68% of revenue from companion animals. Q2 results showed 8% organic sales growth and 15% adjusted earnings growth. Librela sales in the U.S.

Aug 5 (Reuters) - Zoetis (ZTS.N), opens new tab raised annual forecast and beat second-quarter estimates on Tuesday, driven by strong demand for its medicines and vaccines for pets, sending the animal ...

(Reuters) -Zoetis raised annual forecast and beat second-quarter estimates on Tuesday, driven by strong demand for its medicines and vaccines for pets, sending the animal healthcare company's shares ...